IP Library › Granted Patent US 12,310,928
Granted Patent B2
US 12,310,928 · App. 17/099,224 · Granted May 27, 2025

Enthesis healing

Inventors: Robert Z. Tashjian (Salt Lake City, UT); Peter N. Chalmers (Salt Lake City, UT); T. Wade Fallin (Hyde Park, UT); James M. Hotaling (Salt Lake City, UT)
Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
A61K31/05A61K9/7023A61K45/06A61L17/005A61P19/00A61P21/00A61B2017/00893A61B17/0401A61B17/06166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,928
App. No.
17/099,224
Granted
May 27, 2025
Kind
B2
Abstract

Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and/or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.

Claims (46)

1. A method of improving healing of an enthesis of a subject in need thereof, the method comprising:

locally administering, at a site of enthesis repair, a composition comprising

(i) an estrogen at a dose of 0.05 mg to 8 mg, wherein the estrogen comprises one or more of estrone, estradiol, estriol, or estradiol ester,

(ii) an androgen and/or androgen equivalent at a dose of 2.5 mg to 200 mg, wherein the androgen comprises one or more of testosterone, dihydrotestosterone. androstenedione, or testosterone ester, and wherein the androgen equivalent is a selective androgen receptor modulator comprising one or more of enobosarm or ligandrol, or

(iii) combination thereof,

to thereby increase levels of at least one sex steroid at the site of enthesis repair; and

the composition improving healing of the enthesis in the subject.

2. The method of claim 1 , wherein the enthesis is a repaired enthesis.

3. The method of claim 2 , wherein risk of re-tear injury is reduced due to the improved healing of the enthesis.

4. The method of claim 1 , wherein the enthesis is associated with an Achilles tendon, rotator cuff tendon, distal biceps and triceps tendon, pectoralis major tendon, flexor and extensor tendon, wrist extensor and flexor tendon, hip abductor tendon, proximal hamstring tendon, patella tendon, quadriceps tendon, peroneal tendon, toe flexor and extensor tendon, anterior cruciate ligament, posterior cruciate ligament, knee medial and lateral collateral ligament, anterior talofibular ligament, calcaneofibular ligament, posterior talofibular ligament, anterior inferior tibiofibular ligament, posterior inferior tibiofibular ligament, ankle deltoid and spring ligament, acromioclavicular ligament, coracoclavicular ligament, sternoclavicular ligament, elbow lateral collateral ligament, elbow medial collateral ligament, radial annular ligament, ligament of the wrist, plantar plate, or collateral ligament of a finger, thumb, or toe.

5. The method of claim 1 , wherein the composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes.

6. The method of claim 1 , wherein the composition further comprises an aromatase inhibitor.

7. The method of claim 1 , wherein the composition comprises a combination of sex steroids and/or sex steroid equivalents formulated to increase levels of more than one sex steroid in the subject.

8. The method of claim 1 , wherein the composition is administered by way of a drug-eluting implant implanted at or near the site of the enthesis.

9. The method of claim 8 , wherein the drug-eluting implant is a suture, suture anchor, other implant configured for implantation in bone at or near the site of the enthesis, a drug-loaded textile, drug-loaded patch, or combination thereof.

10. The method of claim 1 , wherein the composition further comprises a carrier and is formulated to provide extended release of the composition.

11. A method of improving healing of an enthesis of a subject in need thereof, the method comprising:

locally administering, at a site of enthesis repair, a composition consisting of:

(i) an estrogen, androgen equivalent, or combination thereof,

wherein the estrogen comprises one or more of estrone, estradiol, estriol, or estradiol ester,

wherein the androgen comprises one or more of testosterone, dihydrotestosterone. androstenedione, or testosterone ester,

wherein the androgen equivalent is a selective androgen receptor modulator comprising one or more of enobosarm or ligandrol, and

(ii) optionally, a carrier,

to thereby increase levels of at least one sex steroid at the site of enthesis repair; and

the composition improving healing of the enthesis in the subject.

12. The method of claim 11 , wherein the carrier comprises a solvent, solution, emulsion, suspension, coating, isotonic agent, dispersion media, suspension media, absorption promoting agent, absorption delaying agent, suspending agent, thickening agent, preservative, antimicrobial agent, salt, liposome, polymeric micelle, microsphere, nanoparticles, or combination thereof.

13. The method of claim 11 , wherein the composition is included in an implant, textile, patch, prodrug, or depot drug.

14. The method of claim 11 , wherein administering the composition comprises administering:

(i) the estrogen at a dose of 0.05 mg to 8 mg,

(ii) the androgen and/or the androgen equivalent at a dose of 2.5 mg to 200 mg,

or combination thereof.

15. A method of improving healing of an enthesis of a subject, the method comprising:

locally administering, at a site of enthesis repair, a composition comprising an estrogen, androgen, androgen equivalent, or combination thereof to increase levels of at least one sex steroid at the site of enthesis repair,

wherein the composition omits other active compounds for improving healing of the enthesis,

wherein the estrogen comprises one or more of estrone, estradiol, estriol, or estradiol ester,

wherein the androgen comprises one or more of testosterone, dihydrotestosterone, androstenedione, or testosterone ester,

wherein the androgen equivalent is a selective androgen receptor modulator comprising one or more of enobosarm or ligandrol; and

the composition improving healing of the enthesis in the subject.

16. The method of claim 15 , wherein administering the composition comprises administering:

(i) the estrogen at a dose of 0.05 mg to 8 mg,

(ii) the androgen and/or the androgen equivalent at a dose of 2.5 mg to 200 mg,

or combination thereof.

17. The method of claim 8 , wherein locally administering the composition comprises placing the drug-eluting implant in a formed cavity in a bone.

18. The method of claim 1 , wherein the estradiol ester comprises one or more of estradiol cypionate, estradiol benzoate, estradiol dipropionate, estradiol enanthate, estradiol undecylate, or estradiol valerate, and wherein the testosterone ester comprises testosterone enanthate, testosterone cypionate, testosterone propionate, or testosterone undecanoate.

19. The method of claim 11 , wherein the estradiol ester comprises one or more of estradiol cypionate, estradiol benzoate, estradiol dipropionate, estradiol enanthate, estradiol undecylate, or estradiol valerate, and wherein the testosterone ester comprises testosterone enanthate, testosterone cypionate, testosterone propionate, or testosterone undecanoate.

20. The method of claim 15 , wherein the estradiol ester comprises one or more of estradiol cypionate, estradiol benzoate, estradiol dipropionate, estradiol enanthate, estradiol undecylate, or estradiol valerate, and wherein the testosterone ester comprises testosterone enanthate, testosterone cypionate, testosterone propionate, or testosterone undecanoate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: TASHJIAN, ROBERT Z.; CHALMERS, PETER N.; FALLIN, T. WADE; HOTALING, JAMES M.
To: UNIVERSITY OF UTAH
Reel/Frame 054955/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 054955/0640 →
Continuity (1)
Related Publication 20220151950A1 · May 19, 2022
References Cited (70)
US 4450150A · Sidman · 1984 [cited by applicant]
US 5460820A · Ebert et al. · 1995 [cited by applicant]
US 5783208A · Venkateshwaran et al. · 1998 [cited by applicant]
US 5836935A · Ashton et al. · 1998 [cited by applicant]
US 6139873A · Hughes et al. · 2000 [cited by applicant]
US 6187742B1 · Wozney et al. · 2001 [cited by applicant]
US 6228852B1 · Shaak · 2001 [cited by applicant]
US 6689153B1 · Skiba · 2004 [cited by applicant]
US 6936270B2 · Watson et al. · 2005 [cited by applicant]
US 7625920B2 · Meissner et al. · 2009 [cited by applicant]
US 7741273B2 · McKay · 2010 [cited by applicant]
US 7763582B2 · Lin et al. · 2010 [cited by applicant]
US 7776826B2 · Vignery et al. · 2010 [cited by applicant]
US 7976858B2 · Hotchkiss et al. · 2011 [cited by applicant]
US 8202531B2 · McKay · 2012 [cited by applicant]
US 8354375B2 · Vukicevic et al. · 2013 [cited by applicant]
US 8501690B2 · Stark · 2013 [cited by applicant]
US 8557271B2 · Kimble et al. · 2013 [cited by applicant]
US 8728509B2 · McKay · 2014 [cited by applicant]
US 8870954B2 · Lynch et al. · 2014 [cited by applicant]
US 8895540B2 · Dimauro et al. · 2014 [cited by applicant]
US 8933028B2 · Stark · 2015 [cited by applicant]
US 9440009B2 · Armbruster et al. · 2016 [cited by applicant]
US 9445901B2 · Tunc et al. · 2016 [cited by applicant]
US 9616205B2 · Nebosky et al. · 2017 [cited by applicant]
US 9623152B2 · Ogilvie et al. · 2017 [cited by applicant]
US 9623222B2 · McKay · 2017 [cited by applicant]
US 9642658B2 · Boyd et al. · 2017 [cited by applicant]
US 9642891B2 · Hart et al. · 2017 [cited by applicant]
US 10022233B1 · Gall et al. · 2018 [cited by applicant]
US 10188441B2 · Kim et al. · 2019 [cited by applicant]
US 10258566B2 · Hart et al. · 2019 [cited by applicant]
US 10349993B2 · Nebosky et al. · 2019 [cited by applicant]
US 10369098B2 · Kassab et al. · 2019 [cited by applicant]
US 10441567B2 · Zhi · 2019 [cited by applicant]
US 10456450B2 · Hart et al. · 2019 [cited by applicant]
US 10610570B2 · Riester et al. · 2020 [cited by applicant]
US 10624996B2 · Gall et al. · 2020 [cited by applicant]
US RE49219E · DiMauro et al. · 2022 [cited by applicant]
US 11660373B2 · Carter et al. · 2023 [cited by applicant]
US 11680094B2 · Cao · 2023 [cited by applicant]
US 20040034357A1 · Beane et al. · 2004 [cited by applicant]
US 20060093646A1 · Cima et al. · 2006 [cited by applicant]
US 20070275035A1 · Herman et al. · 2007 [cited by applicant]
US 20080228193A1 · Matityahu · 2008 [cited by applicant]
US 20080234727A1 · Garigapati et al. · 2008 [cited by applicant]
US 20090177229A1 · Gulotta et al. · 2009 [cited by applicant]
US 20110238016A1 · Hotchkiss et al. · 2011 [cited by applicant]
US 20130144250A1 · Schwarz et al. · 2013 [cited by applicant]
US 20140056960A1 · Nanchahal et al. · 2014 [cited by applicant]
US 20140315847A1 · Peck et al. · 2014 [cited by applicant]
US 20170165077A1 · McDonnell · 2017 [cited by applicant]
US 20170224970A1 · Munster et al. · 2017 [cited by applicant]
US 20190083231A1 · Gazit et al. · 2019 [cited by applicant]
US 20190185556A1 · Ominsky et al. · 2019 [cited by applicant]
US 20200170640A1 · Wilson-Wirth et al. · 2020 [cited by applicant]
US 20220226544A1 · Hotchkiss et al. · 2022 [cited by applicant]
WO 2013119582A1 · 2013 [cited by applicant]
WO WO2018031454 · 2018 [cited by examiner]
Alberts D.S. et al., “Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinom… [cited by applicant]
Cornetta K. et al., “A retroviral vector expressing human interferon gamma upregulates MHC antigen expression in human breast cancer and leukemia cell lines”, Cancer Gene Therapy, vol. 1, No. 1, 1994, pp. 91-98. [cited by applicant]
Martini M. et al., “IFN-?-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer”, Vaccine, vol. 28, No. 20, Mar. 19, 2010, pp. 3548-3557. [cited by applicant]
Street D. et al., “Interferon-? Enhances Susceptibility of Cervical Cancer Cells to Lysis by Tumor-Specific Cytotoxic T Cells”, Gynecologic Oncology, vol. 65, No. 2, 1997, pp. 265-272. [cited by applicant]
Barrett-Connor et al., “A Two-Year, Double-Blind Comparison of Estrogen-Androgen and Conjugated Estrogens in Surgically Menopausal Women”, Journal of Reproductive Medicine, vol. 44, No. 2, Dec. 1999, pp. 1012-1020. [cited by applicant]
Guthrie et al., “The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study”, Osteoporos Int, Mar. 24, 2004, vol. 15, pp. 881-886. [cited by applicant]
Hofbauer et al., “Androgen effects on bone metabolism: recent progress and controversies”, European Journal of Endocrinology, 1999, vol. 140, pp. 271-286. [cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 18/732,532, mailed on Aug. 15, 2024, 11 pages. [cited by applicant]
Savvas et al., “Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received received long-term oral oestrogens”, British Journal of Obs… [cited by applicant]
Savvas et al., “Skeletal Effects of Oral Oestrogen Compared with Subcutaneous Oestrogen and Testosterone In Postmenopausal Women”, BMJ: British Medical Journal, vol. 297, No. 6644, Jul. 30, 1988, pp. 331-333. [cited by applicant]
Watts et al., “Comparison of Oral Estrogens and Estrogens Plus Androgen on Bone Mineral Density, Menopausal Symptoms, and Lipid-Lipoprotein Profiles in Surgical Menopause”, Obstetrics & Gynecology, vol. 85, No. 4, Apr. … [cited by applicant]